SciClone seals another deal to expand China CV portfolio
This article was originally published in Scrip
Executive Summary
The China-focused US firm SciClone Pharmaceuticals has struck its second licensing deal in the cardiovascular sector in as many months, this time acquiring rights from Taiwan Liposome Company (TLC) to a therapy for peripheral arterial disease (PAD) in the Chinese market.